CARDIFF ONCOLOGY, INC.
Pagina dedicata companiei CARDIFF ONCOLOGY, INC. listata cu simbolul US.CRDF
Descriere companie[edit | ]
Cardiff Oncology Inc. (cardiffoncology.com) is a clinical-stage biotechnology company. The Company is focused on developing treatment for cancer patients. Its drug candidate includes onvansertib , which is a novel polo-like kinase 1 (PLK1) adenosine triphosphate (ATP) competitive inhibitor with the combination of chemotherapy and targeted therapeutics. The Company's clinical trail includes TROV-052 , a Phase I b/2 open-label clinical trial of onvansertib in combination with standard-of-care low-dose cytarabine (LDAC) , TROV-053 a Phase II open-label clinical trial of onvansertib in combination with Zytiga (abiraterone acetate)/prednisone and TROV-054 a Phase I b/2 open-label clinical trial of onvansertib in combination with FOLFIRI (folinic acid, fluorouracil, and irinotecan) and Avastin (bevacizumab). Its clinical development programs include tumor genomics and biomarker technology to enable assessment of patient response to treatment.
Grafic actiuni companie[edit | ]